Search Results - alzheimer%27s+disease

14 Results

Sort By:

Inhibition of rip kinases for treating neurodegenerative disorders

Unmet NeedNeurodegenerative disorders are a heterogeneous group that includes Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), dementia, and Huntington’s disease. These disorders result from progressive degeneration of the structure, function, and network of neurons in the central nervous...

Published: 5/9/2024 | Inventor(s): Seulki Lee, Han Seok Ko, Ted Dawson, Martin Pomper, Donghoon Kim, Yumin Oh, Seung-Hwan Kwon, Yong Joo Park

Keywords(s): Alzheimer's Disease, Antagonists/Inhibitors, CNS and Neurological Disorders, Disease Indication, Neurodegenerative Diseases, Parkinson's Disease, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Parkinson’s Disease

Stimulation of Dendrite Growth and Spine Formation by Norrin and LGR6: A Target for Therapy in CNS Injury and Degeneration

Unmet NeedAstroglial dysfunction is associated with the development of numerous central nervous system (CNS) diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and Huntington’s disease (HD). Astroglia are the homeostatic cells of the central nervous system and play key roles in the development and support of neuronal...

Published: 5/9/2024 | Inventor(s): Sean Miller, Jeffrey Rothstein

Keywords(s): Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Biologics, CNS and Neurological Disorders, Dementia, Disease Indication, Huntington's Disease, Parkinson's Disease, Protein, Target, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis, Clinical and Disease Specializations > Neurology > Dementia, Technology Classifications > Therapeutic Modalities > Proteins, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Neurology > Huntington's Disease, Clinical and Disease Specializations > Neurology > Parkinson’s Disease

Conditional Tau Mouse Lines that Faithfully Recapitulate Alzheimer’s Disease-like Pathologies

Value Proposition: Effective therapy for Alzheimer’s disease (AD), the most common form of dementia and a devastating illness for the elderly, remains a great unmet need. For translational research and preclinical drug development, animal models that faithfully mimic the cardinal pathological features of AD are critical. A major limitation of current...

Published: 5/9/2024 | Inventor(s): Philip Wong, Donald Price, Tong Li

Keywords(s): Alzheimer's Disease, Basic Research Biomarker, Cell Lines, CNS and Neurological Disorders, Discovery/Research Tools, Disease Indication, In Vitro Research Tool, In Vivo Research Tool, Mouse Cell Lines, Mouse Model, Neurodegeneration

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Geriatrics, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Rare Diseases, Technology Classifications > Research Tools > Animal Models, Technology Classifications > Research Tools > Cell Lines, Clinical and Disease Specializations > Neurology, Technology Classifications > Research Tools

Biomarkers of Alzheimer's and other Diseases of Cognition

Unmet Need Alzheimer’s disease (AD) results in progressive loss of cognitive function. The common methods of AD diagnoses are clinical observations and medical imaging. As new therapies for AD are discovered, there is a need for simple biomarkers that can be related to the disease pathogenesis. Current biomarkers for AD are unreliable and are not highly...

Published: 5/9/2024 | Inventor(s): Paul Worley, Desheng Xu, Meifang Xiao

Keywords(s): Alzheimer's Disease, Biomarker, Clinical Diagnostics, CNS and Neurological Disorders, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Neurodegeneration

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Geriatrics, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Rare Diseases, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Neurology

Oral Glucose Tolerance Test for Mild Cognitive Impairment/Alzheimer's Disease Biomarker Development

UNMET NEEDAlzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. Treatment of Alzheimer’s disease (AD) is significantly hampered by the lack of easily accessible biomarkers that can detect disease presence and predict disease risk...

Published: 5/9/2024 | Inventor(s): Esther Oh, Constantine Lyketsos, Suzanne Craft

Keywords(s): Alzheimer's Disease, Biomarker, Clinical Diagnostics, CNS and Neurological Disorders, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Neurodegeneration

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Geriatrics, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Rare Diseases, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Neurology

TDP-43 Suppression of Non-conserved Cryptic Exons is Compromised in Human Neurodegenerative Diseases

C13621: Suppression of Non-conserved Cryptic Exons is Compromised in Human Neurodegenerative DiseasesAbstractA novel mechanism underlying the suppression of non conserved cryptic exons. This mechanism is essential to maintain intron integrity, and is compromised in ALS-FTD, indicating that loss of function underlies pathogenesis of disease. Publication...

Published: 5/9/2024 | Inventor(s): Philip Wong, Jonathan Ling

Keywords(s): Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Basic Research Biomarker, CNS and Neurological Disorders, Dementia, Discovery/Research Tools, Disease Indication, In Vivo Research Tool, Knock Out Mouse Model, Mouse Model

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Research Tools > Animal Models, Technology Classifications > Research Tools, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis, Clinical and Disease Specializations > Neurology > Dementia

CTD110.6 monoclonal antibody

C03770: CTD110.6 monoclonal antibody Technical Details: O-linked N-acetylglucosamine (O-GlcNAc) is a newly described but ubiquitous dynamic modification of key regulatory proteins in side virtually all multi-cellular eukaryotic cells. Recently, this sugar modification has been shown to be as abundant as protein phosphorylation, often competing with...

Published: 5/9/2024 | Inventor(s): Frank Comer, Gerald Hart

Keywords(s): Alzheimer's Disease, Antibodies, Biologics, Cancers, CNS and Neurological Disorders, Diabetes, Discovery/Research Tools, Disease Indication, Metabolic Disorders, Monoclonal Antibodies, Research Reagent, Therapeutic Matter, Therapeutic Substance, Therapeutics, Translational Research Biomarker

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Diabetes, Clinical and Disease Specializations > Metabolic Diseases, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools > Antibodies, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities

An Inducible Reconstitution and Real-time Quantitative Kinetic System for the Analysis of Catalysis and Inhibition in Membranes

C12181: An assay to evaluate membrane-immersed enzyme kinetics in real time.Novelty: This technology is an inducible and real-time quantitative kinetic assay for the analysis of intra-membrane proteolysis.Value Proposition: Intra-membrane proteases can catalyze hydrolysis immersed within membranes. These enzymes are implicated in diseases such as Alzheimers...

Published: 5/9/2024 | Inventor(s): Seth Dickey, Rosanna Baker, Sinisa Urban

Keywords(s): Alzheimer's Disease, Assay, Clinical Diagnostics, CNS and Neurological Disorders, Disease Indication, In Vitro Diagnostics, Infectious Diseases, Malaria, Parkinson's Disease, Tuberculosis (TB)

Category(s): Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Research Tools > Assays, Technology Classifications > Diagnostics, Technology Classifications > Research Tools, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Infectious Diseases > Malaria, Clinical and Disease Specializations > Infectious Diseases > Tuberculosis (TB), Clinical and Disease Specializations > Neurology > Parkinson’s Disease

MRM Assay Measurement of Amyloid Precursor Protein in Healthy and Alzheimers Disease Cerebrospinal Fluids

C12148: Method for Measuring Amyloid Precursor Proteins for Alzheimer’s DiseaseNovelty: This invention develops a method to measure the concentrations of various forms of Amyloid Precursor Proteins (APP) in cerebrospinal fluid (CSF).Value Proposition: Alzheimer's disease (AD) is the most common form of dementia. There is no cure for the disease....

Published: 5/9/2024 | Inventor(s): Jennifer Van Eyk, Xiaoqian Liu, Richard O'brien

Keywords(s): Alzheimer's Disease, Assay, Biomarker, Clinical Diagnostics, CNS and Neurological Disorders, Disease Indication, In Vitro Diagnostics, Mechanism-of-action Biomarker, Neurodegeneration, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Geriatrics, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Rare Diseases, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Research Tools > Assays, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Neurology, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities

Novel Compounds targeting GAPDH-Siah Cell Death Cascade

C11114: Novel Compounds targeting GAPDH-Siah Cell Death Cascade Novelty: The GAPDH (Glyceraldehyde-3-phosphate dehydrogenase)-Siah cell death cascade is a implicated in several stress mediated disorders and blocking this cascade using novel inhibitors is an attractive strategy for developing cytoprotective agents. Value Proposition: Cell death...

Published: 5/9/2024 | Inventor(s): Neelam Shahani, Toshiaki Saito, David Kass, Eiki Takimoto, Akira Sawa

Keywords(s): Alzheimer's Disease, Antagonists/Inhibitors, Biomarker, CNS and Neurological Disorders, Disease Indication, Huntington's Disease, Mechanism of Action Biomarker, Neurodegenerative Diseases, Non-novel, Novel, Predicted Novelty, Psychiatric Diseases, Repurposed, Schizophrenia, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Psychiatry > Schizophrenia, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Psychiatry, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Huntington's Disease, Clinical and Disease Specializations > Neurology > Parkinson’s Disease

1 2